12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LX1033: Phase II started

Lexicon disclosed in its 4Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 500 and 1,000 mg...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >